Abstract
In this manuscript, we review the literature on the nutrigenetics and pharmacogenetics of vitamin D pathways, with a focus on genes involved in the pharmacokinetic and pharmacodynamic pathways of vitamin D as they have been major research targets. These include: VDR, CYP2R1, CYP27B1, DHCR7/NADSYN1, GC and CYP24A1. So far only 2 genome wide associations studies evaluated the potential role of genetic polymorphisms in the variability in 25 hydroxy vitamin D (25(OH)D) levels. Most of the evidence is based on the candidate gene approach with some conflicting results when it comes to effect size and associating disease outcome with 25(OH)D levels and genetic polymorphisms. Moreover, very little has been done to look at the effect of significant polymorphisms on the response to vitamin D supplementation. Further research is needed on larger population samples of different ethnicities to resolve some of the controversies. In addition, emerging technologies such as next generation sequencing may be a better genotyping alternative in order to detect rare but potentially important genetic variants. Functional studies are also needed to better understand the association results. This includes coupling genotyping data with gene expression studies as well as epigenetic evaluations.
Keywords: Cytochrome P450, epigenetics, nutrigenetics, pharmacogenetics, vitamin D - 25(OH)D.
Current Pharmacogenomics and Personalized Medicine
Title:The Nutrigenetics and Pharmacogenetics of Vitamin D Pathways
Volume: 12 Issue: 2
Author(s): Zainab Awada, Safaa Ossaily and Nathalie K. Zgheib
Affiliation:
Keywords: Cytochrome P450, epigenetics, nutrigenetics, pharmacogenetics, vitamin D - 25(OH)D.
Abstract: In this manuscript, we review the literature on the nutrigenetics and pharmacogenetics of vitamin D pathways, with a focus on genes involved in the pharmacokinetic and pharmacodynamic pathways of vitamin D as they have been major research targets. These include: VDR, CYP2R1, CYP27B1, DHCR7/NADSYN1, GC and CYP24A1. So far only 2 genome wide associations studies evaluated the potential role of genetic polymorphisms in the variability in 25 hydroxy vitamin D (25(OH)D) levels. Most of the evidence is based on the candidate gene approach with some conflicting results when it comes to effect size and associating disease outcome with 25(OH)D levels and genetic polymorphisms. Moreover, very little has been done to look at the effect of significant polymorphisms on the response to vitamin D supplementation. Further research is needed on larger population samples of different ethnicities to resolve some of the controversies. In addition, emerging technologies such as next generation sequencing may be a better genotyping alternative in order to detect rare but potentially important genetic variants. Functional studies are also needed to better understand the association results. This includes coupling genotyping data with gene expression studies as well as epigenetic evaluations.
Export Options
About this article
Cite this article as:
Awada Zainab, Ossaily Safaa and Zgheib K. Nathalie, The Nutrigenetics and Pharmacogenetics of Vitamin D Pathways, Current Pharmacogenomics and Personalized Medicine 2014; 12 (2) . https://dx.doi.org/10.2174/1875692112666140529002223
DOI https://dx.doi.org/10.2174/1875692112666140529002223 |
Print ISSN 1875-6921 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6913 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Pulmonary Hypertension in COPD: Pathophysiology and Therapeutic Targets
Current Drug Targets Current Pharmacological Approach to Restore Endothelial Dysfunction
Cardiovascular & Hematological Agents in Medicinal Chemistry Αlpha-2 Adrenergic and Opioids Receptors Participation in Mice Gastroprotection of Abelmoschus esculentus Lectin
Current Pharmaceutical Design Impact of Cardiovascular Factors on Pulse Wave Velocity and Total Vascular Resistance in Different Age Group Patients with Cardiovascular Disorders
Current Aging Science Clinical Profile of Relaxin, a Possible New Drug for Human Use
Current Drug Safety Rhinovirus-Associated Wheeze During Infancy and Asthma Development
Current Respiratory Medicine Reviews Editorial [Hot Topic:Role of Food and Nutritional Factors in Metabolic Syndrome X,Cancer and Cardiovascular Diseases (Guest Editor: Undurti N. Das)]
Current Nutrition & Food Science The Development of Antibody-based Immunotherapy for Methamphetamine Abuse: Immunization, and Virus-Mediated Gene Transfer Approaches
Current Gene Therapy Pulmonary Vascular Function in Insulin Resistance and Diabetes
Current Vascular Pharmacology Risk and Benefit of Statins in Stroke Secondary Prevention
Current Vascular Pharmacology Pharmacovigilance Assessment of Cardiac Implications of Nicotine Replacement Therapy Among Smokers
Current Drug Safety Diuretic-Associated Electrolyte Disorders in the Elderly: Risk Factors, Impact, Management and Prevention
Current Drug Safety Viral Anti-Inflammatory Reagents: The Potential for Treatment of Arthritic and Vasculitic Disorders
Endocrine, Metabolic & Immune Disorders - Drug Targets Left Ventricular Hypertrophy and Angiotensin II Receptor Blocking Agents
Current Medicinal Chemistry - Cardiovascular & Hematological Agents P2X7 Receptors: Channels, Pores and More
CNS & Neurological Disorders - Drug Targets Heart Failure in East Asia
Current Cardiology Reviews Therapeutic Approaches for Reducing C-Reactive Protein (CRP) Levels and the Associated Cardiovascular Risk
Current Chemical Biology Actions of Relaxin on Non-Reproductive Tissues
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Biomarkers of Asthma: Recent Patents from 2009-2011
Recent Patents on Biomarkers Marine n-3 Fatty Acids for Cardiovascular Risk Reduction and Disease Control in Rheumatoid Arthritis: “Kill Two Birds with One Stone”?
Current Pharmaceutical Design